How does doxorubicin work?

eLife

Volumn 2012, Issue 1, 2012, Pages

  Patel, Anand G ^a   Kaufmann, Scott H ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CREB3L1; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CREB3L1 PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; NERVE PROTEIN; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CYTOTOXICITY; DOWN REGULATION; GENE EXPRESSION; HUMAN; LIPID METABOLISM; PROTEIN DEGRADATION; VIRUS INFECTION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NERVE TISSUE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878982435     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.00387     Document Type: Article

References (9)

1. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-7. doi: 10.1038/nature11003.
2. Denard B, Seemann J, Chen Q, Gay A, Huang H, Chen Y, et al. 2011. The membrane-bound transcription factor CREB3L1 is activated in response to virus infection to inhibit proliferation of virus-infected cells. Cell Host Microbe 10:65-74. doi: 10.1016/j.chom.2011.06.006.
3. Denard B, Lee C, Ye J. 2012. Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. eLife 1:e00090. doi: 10.7554/elife.00090.
4. Gewirtz D. 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 57:727-41. doi: 10.1016/S00062952(98)003074.
5. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. 2001. Anthracyclineinduced clinical heart failure in a cohort of 607 children: longterm followup study. J Clin Oncol 19:191-6.
6. Lal M, Caplan M. 2011. Regulated intramembrane proteolysis: signaling pathways and biological functions. Physiology (Bethesda) 26:34-44. doi: 10.1152/physiol.00028.2010.
7. Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H, et al. 1999. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 38:10793-800. doi: 10.1021/bi9909804.
8. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229. doi: 10.1124/pr.56.2.6.
9. Zhang S, Liu X, BawaKhalfe T, Lu LS, Lyu YL, Liu LF, et al. 2012. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 18:1639-42. doi: 10.1038/nm.2919.